KBC Group NV boosted its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 16.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 371,225 shares of the biopharmaceutical company’s stock after acquiring an additional 51,770 shares during the quarter. KBC Group NV’s holdings in Bristol-Myers Squibb were worth $23,480,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Van ECK Associates Corp lifted its position in Bristol-Myers Squibb by 0.7% in the 3rd quarter. Van ECK Associates Corp now owns 791,275 shares of the biopharmaceutical company’s stock valued at $50,436,000 after acquiring an additional 5,451 shares in the last quarter. D.A. Davidson & CO. lifted its position in Bristol-Myers Squibb by 8.6% in the 3rd quarter. D.A. Davidson & CO. now owns 205,789 shares of the biopharmaceutical company’s stock valued at $13,117,000 after acquiring an additional 16,310 shares in the last quarter. First Interstate Bank lifted its position in Bristol-Myers Squibb by 6.3% in the 3rd quarter. First Interstate Bank now owns 118,681 shares of the biopharmaceutical company’s stock valued at $7,565,000 after acquiring an additional 7,030 shares in the last quarter. Hills Bank & Trust Co. lifted its position in Bristol-Myers Squibb by 11.2% in the 4th quarter. Hills Bank & Trust Co. now owns 16,396 shares of the biopharmaceutical company’s stock valued at $1,005,000 after acquiring an additional 1,646 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its position in Bristol-Myers Squibb by 137.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 75,000 shares of the biopharmaceutical company’s stock valued at $4,781,000 after acquiring an additional 275,000 shares in the last quarter. 71.29% of the stock is currently owned by institutional investors and hedge funds.
NYSE:BMY opened at $52.24 on Tuesday. The company has a quick ratio of 1.39, a current ratio of 1.52 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $86.16 billion, a PE ratio of 17.36, a P/E/G ratio of 1.32 and a beta of 0.99. Bristol-Myers Squibb Co has a one year low of $49.96 and a one year high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 26th. The biopharmaceutical company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.85 by $0.09. The firm had revenue of $5.19 billion during the quarter, compared to analyst estimates of $5.25 billion. Bristol-Myers Squibb had a return on equity of 37.56% and a net margin of 4.37%. Bristol-Myers Squibb’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.84 EPS. sell-side analysts expect that Bristol-Myers Squibb Co will post 3.41 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th were paid a $0.40 dividend. The ex-dividend date of this dividend was Thursday, April 5th. This represents a $1.60 annualized dividend and a dividend yield of 3.06%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 53.16%.
Several equities analysts recently issued reports on BMY shares. Citigroup set a $78.00 price objective on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Friday, February 16th. Argus reaffirmed a “buy” rating and issued a $66.43 price objective (down from $75.00) on shares of Bristol-Myers Squibb in a research report on Wednesday, March 21st. TheStreet cut Bristol-Myers Squibb from a “b” rating to a “c+” rating in a research report on Thursday, March 8th. Morgan Stanley cut Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and upped their price objective for the company from $54.08 to $58.00 in a research report on Tuesday, April 17th. Finally, Barclays lowered their price objective on Bristol-Myers Squibb from $65.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Friday, April 27th. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $62.84.
In related news, Director Dinesh C. Paliwal acquired 4,770 shares of Bristol-Myers Squibb stock in a transaction dated Monday, April 30th. The stock was purchased at an average cost of $52.40 per share, for a total transaction of $249,948.00. Following the purchase, the director now directly owns 8,027 shares of the company’s stock, valued at approximately $420,614.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.12% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.